Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource
To drive high-quality omics translational research using The Cancer Genome Atlas (TCGA) data, a TCGA Pan-Cancer Clinical Data Resource was proposed. However, there is an out-of-step issue between clinical outcomes and the omics data of TCGA for skin cutaneous melanoma (SKCM), due to the majority of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/3/280 |
| _version_ | 1797763061661040640 |
|---|---|
| author | Jie Xiong Zhitong Bing Shengyu Guo |
| author_facet | Jie Xiong Zhitong Bing Shengyu Guo |
| author_sort | Jie Xiong |
| collection | DOAJ |
| description | To drive high-quality omics translational research using The Cancer Genome Atlas (TCGA) data, a TCGA Pan-Cancer Clinical Data Resource was proposed. However, there is an out-of-step issue between clinical outcomes and the omics data of TCGA for skin cutaneous melanoma (SKCM), due to the majority of metastatic samples. In clinical cases, the survival time started from the initial SKCM diagnosis, while the omics data were characterized at TCGA sampling. This study aimed to address this issue by proposing an observed survival interval (OBS), which was defined as the time interval from TCGA sampling to patient death or last follow-up. We compared the OBS with the usual recommended overall survival (OS) by associating them with both clinical data and microRNA sequencing data of TCGA-SKCM. We found that the OS of primary SKCM was significantly shorter than that of metastatic SKCM, while the opposite happened if OBS was compared. OS was associated with the pathological stage of both primary and metastatic SKCM, while OBS was associated with the pathological stage of primary SKCM but not that of metastatic SKCM. Five previously cross-validated survival-associated microRNAs were found to be associated with the OBS rather than OS in metastatic SKCM. Thus, the OBS was more appropriate for associating microRNA-omics data of TCGA-SKCM than OS, and it is a timely supplement to TCGA Pan-Cancer Clinical Data Resource. |
| first_indexed | 2024-03-12T19:36:12Z |
| format | Article |
| id | doaj.art-2747ceac8cf24a8a801066d2bb29a35e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:36:12Z |
| publishDate | 2019-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-2747ceac8cf24a8a801066d2bb29a35e2023-08-02T04:09:13ZengMDPI AGCancers2072-66942019-02-0111328010.3390/cancers11030280cancers11030280Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data ResourceJie Xiong0Zhitong Bing1Shengyu Guo2Department of Epidemiology and Health Statistics, XiangYa School of Public Health, Central South University, Changsha 410078, ChinaDepartment of Computational Physics, Institute of Modern Physics of Chinese Academy of Sciences, Lanzhou 730000, ChinaDepartment of Epidemiology and Health Statistics, XiangYa School of Public Health, Central South University, Changsha 410078, ChinaTo drive high-quality omics translational research using The Cancer Genome Atlas (TCGA) data, a TCGA Pan-Cancer Clinical Data Resource was proposed. However, there is an out-of-step issue between clinical outcomes and the omics data of TCGA for skin cutaneous melanoma (SKCM), due to the majority of metastatic samples. In clinical cases, the survival time started from the initial SKCM diagnosis, while the omics data were characterized at TCGA sampling. This study aimed to address this issue by proposing an observed survival interval (OBS), which was defined as the time interval from TCGA sampling to patient death or last follow-up. We compared the OBS with the usual recommended overall survival (OS) by associating them with both clinical data and microRNA sequencing data of TCGA-SKCM. We found that the OS of primary SKCM was significantly shorter than that of metastatic SKCM, while the opposite happened if OBS was compared. OS was associated with the pathological stage of both primary and metastatic SKCM, while OBS was associated with the pathological stage of primary SKCM but not that of metastatic SKCM. Five previously cross-validated survival-associated microRNAs were found to be associated with the OBS rather than OS in metastatic SKCM. Thus, the OBS was more appropriate for associating microRNA-omics data of TCGA-SKCM than OS, and it is a timely supplement to TCGA Pan-Cancer Clinical Data Resource.https://www.mdpi.com/2072-6694/11/3/280overall survivalobserved survival intervalskin cutaneous melanomaThe Cancer Genome Atlasomics |
| spellingShingle | Jie Xiong Zhitong Bing Shengyu Guo Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource Cancers overall survival observed survival interval skin cutaneous melanoma The Cancer Genome Atlas omics |
| title | Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource |
| title_full | Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource |
| title_fullStr | Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource |
| title_full_unstemmed | Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource |
| title_short | Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource |
| title_sort | observed survival interval a supplement to tcga pan cancer clinical data resource |
| topic | overall survival observed survival interval skin cutaneous melanoma The Cancer Genome Atlas omics |
| url | https://www.mdpi.com/2072-6694/11/3/280 |
| work_keys_str_mv | AT jiexiong observedsurvivalintervalasupplementtotcgapancancerclinicaldataresource AT zhitongbing observedsurvivalintervalasupplementtotcgapancancerclinicaldataresource AT shengyuguo observedsurvivalintervalasupplementtotcgapancancerclinicaldataresource |